Compelling evidence has recently emerged that Abs against PAR-1 are present in SSc patients with SRC, a life-threatening complication of SSc, which agonistically induce PAR-1 activation through signaling pathways involved in the production of pro-inflammatory factors such as IL-6 (6). This evidence concerns the gene IL6 and systemic sclerosis.